Alnylam to Webcast Conference Call Discussing First Quarter 2017 Financial Results
April 27 2017 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it will report financial
results for the first quarter ending March 31, 2017 on Friday, May
5, 2017, before the U.S. financial markets open.
Management will provide an update on the company and discuss
first quarter 2017 results as well as expectations for the future
via conference call on Friday, May 5, 2017 at 8:30 a.m. ET. To
access the call, please dial 877-312-7507 (domestic) or
631-813-4828 (international) five minutes prior to the start time
and refer to conference ID 13425320. A replay of the call will be
available beginning at 11:30 a.m. ET on the day of the call. To
access the replay, please dial 855-859-2056 (domestic) or
404-537-3406 (international), and refer to conference ID
13425320.
A live audio webcast of the call will be available on the
Investors section of the company's website, www.alnylam.com. An
archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a whole new
class of innovative medicines with the potential to transform the
lives of patients who have limited or inadequate treatment options.
Based on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of a wide
range of debilitating diseases. Founded in 2002, Alnylam is
delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform and deep pipeline of
investigational medicines, including three product candidates that
are in late-stage development or will be in 2017. Looking forward,
Alnylam will continue to execute on its “Alnylam 2020” strategy of
building a multi-product, commercial-stage biopharmaceutical
company with a sustainable pipeline of RNAi-based medicines. For
more information about our people, science and pipeline, please
visit www.alnylam.com and engage with us on Twitter at
@Alnylam.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170427005151/en/
Alnylam Pharmaceuticals, Inc.Christine Regan Lindenboom,
617-682-4340(Investors and Media)orJosh Brodsky,
617-551-8276(Investors)
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024